Keywords: positive, new, data, adjustable, symbicort, astrazeneca, released
Positive new data for adjustable Symbicort
Article | 15 September 2003
AstraZeneca has released promising findings from a head-to-head trial comparing adjustable-dosing of its Symbicort (budesonide/formoterol) with a fixed-dose of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
